# RGS19

## Overview
RGS19, or Regulator of G Protein Signaling 19, is a gene that encodes a member of the RGS protein family, specifically involved in the modulation of G protein-coupled receptor (GPCR) signaling pathways. The protein product of RGS19, also known as GAIP, functions as a GTPase-activating protein (GAP) for Gα subunits, facilitating the inactivation of G proteins by accelerating the hydrolysis of GTP to GDP. This regulatory activity is crucial for controlling signal transduction processes that influence various physiological functions, including growth, differentiation, and metabolism (AbramowNewerly2006RGS). RGS19 is characterized by a conserved RGS domain and a unique carboxy-terminal PDZ binding motif, which allows it to interact with PDZ domain-containing proteins such as GIPC, playing a significant role in receptor signaling pathways, including those involving the D2 dopaminergic receptor (AbramowNewerly2006RGS). The protein's interactions and regulatory functions have implications in various cellular processes and diseases, notably in cancer progression, where it has been identified as a potential prognostic marker and therapeutic target (Ke2024RGS19).

## Structure
RGS19, also known as GAIP, is a member of the RZ subfamily of Regulator of G Protein Signaling proteins. It contains a conserved RGS domain, which is approximately 130 amino acids in length and functions as a GTPase-activating protein (GAP) for Gα subunits, accelerating their GTP hydrolysis and returning them to an inactive GDP-bound state (Tesmer2009Chapter). The RGS domain is characterized by nine alpha helices, which are conserved across most RGS isoforms (Shaw2019An).

RGS19 has a unique structural feature, a carboxy-terminal PDZ binding motif, which facilitates its interaction with PDZ domain-containing proteins such as GIPC. This interaction is crucial for its role in specific receptor signaling pathways, including those involving the D2 dopaminergic receptor (AbramowNewerly2006RGS).

The protein's flexibility and inhibitor potency are influenced by the presence of interhelical salt bridges. RGS19 has a single conserved salt bridge between E125 and K138, which is less than those found in RGS4 and RGS8, contributing to its higher flexibility and potent inhibition by specific inhibitors (Shaw2019An). The L118D mutation in RGS19 introduces an additional salt bridge, enhancing its thermal stability and altering its interaction with inhibitors (Shaw2019An).

## Function
RGS19, also known as GAIP, is a member of the RGS protein family that plays a critical role in modulating G protein-coupled receptor (GPCR) signaling pathways. It functions as a GTPase-activating protein (GAP) for Gα subunits, accelerating the hydrolysis of GTP to GDP, which inactivates G proteins and thus regulates signal transduction (AbramowNewerly2006RGS). RGS19 is primarily active in the cytoplasm and plasma membrane, where it influences various physiological processes, including growth, differentiation, and metabolism (AbramowNewerly2006RGS).

RGS19 interacts with GIPC, a PDZ domain-containing scaffolding protein, forming a complex that is involved in receptor stabilization and signal transduction inhibition. This complex is recruited to the plasma membrane following the activation of the D2 dopamine receptor, where it stabilizes the receptor, aids in receptor trafficking, and inhibits the signal transduction pathway (AbramowNewerly2006RGS). The RGS19-GIPC interaction also plays a role in vesicular trafficking and endocytosis, independent of RGS19's GAP activity (AbramowNewerly2006RGS).

RGS19 is involved in the regulation of GPCR signaling by targeting specific receptors, such as the D2 dopaminergic receptor, and potentially influencing their signaling outcomes (AbramowNewerly2006RGS). It also participates in cross-talk between G protein and non-G protein signaling networks, affecting downstream signaling events (AbramowNewerly2006RGS).

## Clinical Significance
RGS19 has been implicated in the progression of hepatocellular carcinoma (HCC). Elevated expression of RGS19 in HCC tissues is associated with poor prognosis, larger tumor size, higher AFP levels, advanced TNM stage, and reduced overall and disease-free survival. RGS19 promotes HCC cell proliferation and metastasis, and its knockdown reduces proliferation and increases apoptosis in HCC cells. These findings suggest that RGS19 is an independent prognostic factor for HCC and a potential target for therapeutic intervention (Ke2024RGS19).

RGS19 stabilizes the MYH9 protein by preventing its degradation through competition with the E3 ubiquitin ligase STUB1. This stabilization activates the β-catenin/c-Myc signaling axis, forming a positive feedback loop that promotes HCC development. The interaction between RGS19 and MYH9 is crucial for maintaining MYH9 protein stability, which is essential for RGS19-mediated HCC progression (Ke2024RGS19).

In addition to HCC, RGS19 expression is linked to poor prognosis in other cancers, such as prostate and ovarian cancer, and it promotes bladder cancer cell proliferation. These associations highlight the clinical significance of RGS19 expression alterations in cancer progression (Ke2024RGS19).

## Interactions
RGS19 interacts with several proteins, playing a significant role in various cellular processes. It interacts with MYH9 in hepatocellular carcinoma (HCC) cells, where the RGS domain of RGS19 binds to the motor domain of MYH9. This interaction stabilizes MYH9 by preventing its proteasome-mediated degradation, which is typically facilitated by the E3 ubiquitin ligase STUB1. RGS19 competes with STUB1 for binding to MYH9, thereby reducing MYH9 polyubiquitination and degradation (Ke2024RGS19).

RGS19 also interacts with Gα subunits of heterotrimeric G proteins, acting as a GTPase-activating protein (GAP) to accelerate their inactivation. It was initially identified through its interaction with Gα i3 and can modulate signaling pathways by interacting with GIPC, a PDZ domain-containing protein. This interaction is crucial for maintaining cancer cell proliferation and involves various receptors and membrane-associated proteins (Wang2024RGS19).

In the context of zVAD-induced autophagy and cell death, RGS19 interacts with RIP3 and GNAI3. These interactions are essential for zVAD-induced pathways, highlighting RGS19's role in autophagic processes and cell death regulation (Wu2014Regulator).


## References


[1. (AbramowNewerly2006RGS) Maria Abramow-Newerly, Anju A. Roy, Caroline Nunn, and Peter Chidiac. Rgs proteins have a signalling complex: interactions between rgs proteins and gpcrs, effectors, and auxiliary proteins. Cellular Signalling, 18(5):579–591, May 2006. URL: http://dx.doi.org/10.1016/J.CELLSIG.2005.08.010, doi:10.1016/j.cellsig.2005.08.010. This article has 300 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/J.CELLSIG.2005.08.010)

[2. (Shaw2019An) Vincent S. Shaw, Mohammadjavad Mohammadi, Josiah A. Quinn, Harish Vashisth, and Richard R. Neubig. An interhelical salt bridge controls flexibility and inhibitor potency for regulators of g-protein signaling proteins 4, 8, and 19. Molecular Pharmacology, 96(6):683–691, September 2019. URL: http://dx.doi.org/10.1124/mol.119.117176, doi:10.1124/mol.119.117176. This article has 8 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1124/mol.119.117176)

[3. (Wu2014Regulator) Ting Wu, Yuanyue Li, Deli Huang, Felicia Han, Ying-Ying Zhang, Duan-Wu Zhang, and Jiahuai Han. Regulator of g-protein signaling 19 (rgs19) and its partner gα-inhibiting activity polypeptide 3 (gnai3) are required for zvad-induced autophagy and cell death in l929 cells. PLoS ONE, 9(4):e94634, April 2014. URL: http://dx.doi.org/10.1371/journal.pone.0094634, doi:10.1371/journal.pone.0094634. This article has 12 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0094634)

[4. (Ke2024RGS19) Shanjia Ke, Shounan Lu, Yanan Xu, Miaoyu Bai, Hongjun Yu, Bing Yin, Chaoqun Wang, Zhigang Feng, Zihao Li, Jingjing Huang, Xinglong Li, Baolin Qian, Yongliang Hua, Yao Fu, Bei Sun, Yaohua Wu, and Yong Ma. Rgs19 activates the myh9/β-catenin/c-myc positive feedback loop in hepatocellular carcinoma. Experimental &amp; Molecular Medicine, 56(6):1412–1425, June 2024. URL: http://dx.doi.org/10.1038/s12276-024-01244-9, doi:10.1038/s12276-024-01244-9. This article has 1 citations.](https://doi.org/10.1038/s12276-024-01244-9)

[5. (Tesmer2009Chapter) John J.G. Tesmer. Chapter 4 Structure and Function of Regulator of G Protein Signaling Homology Domains, pages 75–113. Elsevier, 2009. URL: http://dx.doi.org/10.1016/S1877-1173(09)86004-3, doi:10.1016/s1877-1173(09)86004-3. This article has 77 citations.](https://doi.org/10.1016/S1877-1173(09)86004-3)

6. (Wang2024RGS19) RGS19 inhibits oncogene-induced neoplastic transformation. This article has 0 citations.